Article Text

Download PDFPDF
Systematic review
α-blockers and antibiotics, alone or in combination, improve symptoms in men with chronic prostatitis/chronic pelvic pain syndrome
  1. Gianpaolo Perletti1,
  2. Vittorio Magri2
  1. 1Laboratory of Toxicology and Pharmacology, Department of Structural and Functional Biology, Università degli Studi dell'Insubria, Busto Arsizio, Italy
  2. 2Urology and Sonography Secondary Care Clinic, Azienda Ospedaliera Istituti Clinici di Perfezionamento, Milano, Italy
  1. Correspondence to Gianpaolo Perletti
    Dipartimento di Biologia Strutturale e Funzionale, Università degli Studi dell'Insubria, Via Alberto Da Giussano 12, 21052 Busto Arsizio, Italy; gianpaolo.perletti{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


Prostatitis represents the most frequent urological diagnosis in men below 50 years of age and the third most common diagnosis among individuals beyond that age.1 Chronic prostatitis (CP) syndromes are traditionally classified as bacterial or abacterial. CP/chronic pelvic pain syndrome (CPPS) (National Institutes of Health (NIH) category III) is diagnosed when patients show signs and symptoms of prostatitis and pelvic pain without evidence of prostatic bacterial infection. Years of clinical research failed to discover a single aetiological factor for CP/CPPS. Therefore, therapy for CP/CPPS is essentially symptomatic and involves the use of antibacterial agents, α-blockers, anti-inflammatory drugs, phytotherapy and so on – alone or in combination.


MEDLINE and EMBASE databases were searched for randomised controlled trials (RCTs) in which patients met NIH …

View Full Text


  • Competing interests GP has been a consultant for Astellas Pharma. VM has no competing interests to declare.